key: cord-0777793-b3nef9si authors: Kondili, Loreta A.; Craxì, Lucia; Andreoni, Massimo; Mennini, Francesco S.; Razavi, Homie title: Opportunistic co‐screening for HCV and COVID‐19‐related services: A creative response with a need for thoughtful reflection date: 2022-04-21 journal: Liver Int DOI: 10.1111/liv.15243 sha: 7f7bf9379da28ae71e49b09a72199c7a6ef1821f doc_id: 777793 cord_uid: b3nef9si nan Opportunistic co-screening for HCV and COVID-19-related services: A creative response with a need for thoughtful reflection At a time when hepatitis C virus clearance can be obtained by DAAs in almost all infected patients, global infection burden control is an objective within reach, even if achieving the WHO HCV elimination targets by 2030 may not be attainable. 1 The lowest cost intervention is an awareness campaign to bring in those who are recently diagnosed and those who were previously diagnosed but not treated. Only 30% of all HCV-diagnosed patients are linked-to-care. 2 The next level of intervention is case-finding for disease control and screening. Screening invites people who do not have symptoms to undergo testing, whereas health professionals are focused on detecting conditions as early as possible among people with symptoms to avoid late clinical presentation. 3, 4 With continuous efforts for disease control as a priority, early diagnosis in those with liver disease, but unknown HCV status, is the key intervention to avoid further disease progression and costs ( Figure 1 ). To achieve HCV elimination, screening programs in the general population, who are unaware of the infection status, are needed, focusing on the social and age groups most at risk for viral transmission. 5 Universal screening, while theoretically feasible and conceivably highly effective in identifying most HCV-infected persons, would put major organizational and financial hurdles in countries with low-to-moderate prevalence. [6] [7] [8] Hence, if appropriately conceived, focused screenings would identify a high rate of infected subjects, because of the higher infection rate related to risk factors, and simultaneously reduce onward viral transmission by allowing to clear HCV from those at higher risk of spreading the infection. [9] [10] [11] [12] [13] An important step in deciding on a mass screening program is (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) , to detect those persons most exposed to risk factors, specifically, prior or current drug use, tattoos and other at-risk cosmetics or nosocomial interventions. 8 These individuals are asymptomatic, because of the short time of chronic infection and have a low awareness of their exposure risk and disease progression. In light of these considerations and based on HCV elimination goals, screening firstly this cohort would be the most cost-effective strategy to reduce both the infection prevalence and incidence. 8, 16 One of the models proposed to contain the medical and nonmedical infrastructure costs and to reach the targeted population is HCV screening to be held simultaneously with SARS-CoV-2 testing or COVID-19 vaccination. 17 Two papers published in this issue of Liver International address HCV screening during COVID-19 vaccination in Milan (Italy) and during SARS-CoV-2 testing and COVID-19 vaccination in Salerno (Italy). 8, 9 The approaches are reported as an HCV testing opportunity; however, several concerns on the expected HCV prevalence have been raised. The active infection prevalence was found to range from 0.07% to 0.1%, less than the estimated prevalence. 14, 18, 19 These pilot studies pose a matter of debate if the screening program extension to subjects born before 1969 could lead to improved HCV screening effectiveness. Pilot testing can be an important preparatory step to scaling up the screening, but it should be representative of the average conditions of the target population in which the large-scale screening program will function. 2,3 The success of any screening program will be determined by its coverage, uptake, which is the proportion of people who were invited and actually get screened, and linkage to care. Both studies did not report sufficient data to evaluate the sam- Implementing and sustaining a screening program requires extensive human resources and health system capacity. As a rule of thumb, real-life cost evaluations are useful in adapting a screening program. In both Italian studies, owing to the low prevalence of active infection found, the cost per detection of an active infection is shown to be high. 18, 19 The data of both studies could be of help in determining the best resources allocation in the different options of screening settings. However, these estimations are not sufficient to query the costeffectiveness of a mass screening which requires Health Technology Assessment tools that evaluate the cost versus the long-term efficacy of a public health intervention. With specific regard to HCV screening, it is evaluated as a cost-effective intervention, including all screening and disease costs over time, in different countries and with particular regards in Italy, the best cost-effectiveness profile was given by a graduated strategy. [6] [7] [8] Each strategy was weighted for the uncertainties on the prevalence values of active infection, evaluating the short-mid and long-term costs and benefits to the health system in the perspective of achieving the elimination by 2030. 8 Because a screening program is not just a single test but rather a pathway that starts by identifying the eligible people and stops when the outcomes are reported, the further F I G U R E 1 HCV screening for disease control and infection burden reduction Type of prevention in both Italian studies, the increasing costs cannot be justified. 18, 19 In conclusion, despite the feasibility of this opportunistic approach, we strongly believe that HCV screening with COVID-19related services is a chance too good to be missed, but should not be a potential generator of chance findings that could distract from the main aim of HCV elimination. All authors declare no conflict of interest related to the subject matter of this paper. No funds were used for this Editorial. The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination Screening Program a Short Guide Increased Effectiveness Maximize Benefits and Minimize Harm. World Health Organization; 2020 When is it appropriate and how can we get it right? Health systems and policy analysis Progress towards elimination goals for viral hepatitis Assessing the costeffectiveness of hepatitis C screening strategies in France Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era Optimization of hepatitis C virus screening strategies by birth cohort in Italy HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy SEIEVA collaborating group. Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: results from the national surveillance system Incidence and risk factors for hepatitis C virus infection among illicit drug users in Italy Forecasting hepatitis C liver disease burden on real-life data. Does the "hidden iceberg" matter to reach the elimination goals? Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions Milestones to reach hepatitis C virus (HCV) elimination in Italy: from free-of-charge screening to regional roadmaps for an HCV-free nation Absolute targets for HCV elimination and national health policy paradigms: foreseeing future requirements Implementation of HCV screening in the 1969-1989 birth cohort undergoing COVID-19 vaccination: a pivotal study in Italy Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: a prospective modelling analysis